索拉非尼治疗FLT3-ITD阳性的难治性急性髓系白血病1例

齐凌; 黄瑞滨

doi:10.13201/j.issn.1004-2806.2014.01.021

索拉非尼治疗FLT3-ITD阳性的难治性急性髓系白血病1例

齐凌,
黄瑞滨^,

- 南昌大学第一附属医院(南昌, 330006)

详细信息

通讯作者: 黄瑞滨,E-mail:rbhuang69@163.com

中图分类号: R733.71

收稿日期: 2013-10-15

Sorafenib in the treatment of refractory FLT3-ITD positive acute myeloid leukemia:a case report

QI Ling,
HUANG Ruibin^,

More Information

Corresponding author: HUANG Ruibin, E-mail: rbhuang69@163.com

Received Date: 15 October 2013

摘要

- 白血病,髓系,急性 /
- 索拉非尼 /
- FMS样酪氨酸激酶3
Abstract: Clinical and laboratory characteristics of an acute myeloid leukemia patient with FLT3-ITD positive were reported.The application of sorafenib combined with chemotherapy made the patient get the opportunity of bone marrow transplantation.No obvious adverse reactions occurred in the patient taking sorafenib process,and it achieved clinical and molecular remission after bone marrow transplantation.It suggested that sorafenib was safe and effective in the treatment of refractory FLT3-ITD positive acute myeloid leukemia.
- acute myeloid leukemia /
- sorafenib /
- FMS-like tyrosine kinase 3

HTML全文

参考文献(13)

[1]	魏述宁,魏辉,秘营昌,等.索拉非尼联合化疗治疗FLT3-ITD阳性急性单核细胞白血病一例报告及相关文献复习[J].中华血液学杂志,2011,32(1):8-11.
[2]	王云贵,刘旭辉,梁毅,等.FLT3基因表达水平及内部串联重复突变与急性髓系白血病的关系及临床意义[J].中华血液学杂志,2008,29(11):741-745.
[3]	王莉红,周春林,张新伟,等.FLT3基因内部串联重复突变与急性白血病的关系及临床意义[J].中华血液学杂志,2004,25(7):393-396.
[4]	KOTTARIDIS P D,GALE R E,FREW M E,et al.The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy:analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials[J].Blood,2001,98:1752-1759.
[5]	MESHINCHI S,WOODS W G,STIREWALT D L,et al.Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia[J].Blood,2001,97:89-94.
[6]	ZHANG W,KONOPLEVA M,SHI Y X,et al.Mutant FLT3:a direct target of sorafenib in acute myelogenous leukemia[J].J Natl Cancer Inst,2008,100:184-198.
[7]	CHOUDHARY C,MULLER-TIDOW C,BERDEL W E,et al.Signal transduction of oncogenic Flt3[J].Int J Hematol,2005,82:93-99.
[8]	PRATZ K W,SATO T,MURPHY K M,et al.FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML[J].Blood,2010,115:1425-1432.
[9]	SAFAIAN N N,CZIBERE A,BRUNS I,et al.Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia[J].Leuk Res,2009,33:348-350.
[10]	马亮,马一盖.FLT3-ITD突变检测及其临床意义[J].中日友好医院学报,2011,25(3):178-180,184.
[11]	METZELDER S,WANG Y,WOLLMER E,et al.Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia:sustained regression before and after allogeneic stem cell transplantation[J].Blood,2009,113:6567-6571.
[12]	管考鹏,马建辉,孙燕.索拉非尼的毒副作用及处理[J].癌症进展,2007,5(4):370-373,345.
[13]	RAVANDI F,CORTES JE,JONES D,et al.Phase I/II study of combination therapy with sorafenib,idarubicin,and cytarabine in younger patients with acute myeloid leukemia[J].J Clin Oncol,2010,28:1856-1862.